Vertex to acquire Crinetics in $10B foray into endocrine disease drugs

Summary

Vertex Pharmaceuticals agreed to acquire Crinetics Pharmaceuticals for $10 billion to gain two endocrine disease drugs with projected peak annual sales exceeding $5 billion, though the high acquisition price prompted debate among analysts and investors.